Circulating CA-195 in hepatocellular carcinoma and metastatic hepatic carcinoma.
This study was conducted to determine the role of a relatively new tumor marker, CA-195, in the diagnosis of hepatocellular carcinoma and metastatic hepatic carcinoma, and in distinguishing between these two conditions. CA-195 levels were measured using a commercially available immunoradiometric assay (Tandem-R CA-195) in 30 black inpatients with hepatocellular carcinoma, 15 metastatic carcinoma, 10 with amoebic liver abscess, 10 with cirrhosis and 10 normal individuals at King Edward VIII Hospital, Durban. A cutt-off value of 10 u/ml was used. The sensitivity and specificity of CA-195 in hepatocellular carcinoma and metastatic carcinoma was 60% and 22%, and 87% and 42% respectively. False positive results occurred in 5 (50%) patients with amoebic liver abscess, 10 (100%) with cirrhosis and 2 (20%) normal individuals. These results indicate this tumor marker as of limited value in the diagnosis of hepatocellular carcinoma and metastatic carcinoma, and in distinguishing between these conditions.
Maharaj
B
B
Department of Experimental and Clinical Pharmacology, University of Natal Medical School, Durban, South Africa.
Pillay
S
S
Padayachi
T
T
D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood; D006528:Carcinoma, Hepatocellular / Q000097:blood* / Q000453:epidemiology / Q000276:immunology; D003937:Diagnosis, Differential; D005069:Evaluation Studies as Topic; D005188:False Negative Reactions; D005189:False Positive Reactions; D006801:Humans; D015592:Immunoradiometric Assay; D008113:Liver Neoplasms / Q000097:blood* / Q000453:epidemiology / Q000276:immunology; D009362:Neoplasm Metastasis / Q000175:diagnosis* / Q000276:immunology; D012680:Sensitivity and Specificity; D013019:South Africa / Q000453:epidemiology
D015295:Antigens, Tumor-Associated, Carbohydrate